We sought to understand whether giving patients additional consolidation chemotherapy prior to transplant might be an effective tool to reduce the risk of relapse after transplant through the use of a large retrospective database. A theoretical framework was developed based on previous publications to help guide the project. Potential confounding variables from the database were identified using this theoretical framework. Patients who received consolidation chemotherapy prior to transplant were compared to patients who did not receive consolidation chemotherapy. After multivariate analysis, there was no difference in overall survival between groups. This study suggests that clinicians should not routinely administer consolidation chemotherapy with the aim of reducing relapse rates and improving outcomes after transplant